Enterprise Value
20.39M
Cash
231.6M
Avg Qtr Burn
-18.24M
Short % of Float
9.24%
Insider Ownership
3.31%
Institutional Own.
-
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ADI-001 (allogeneic CAR gamma-delta T cell therapy) Details Non-Hodgkin lymphoma, Cancer Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 1 Update |